Valuation dashboard for Elanco Animal Health Incorporated (ELAN) with P/E N/A, P/B 1.83, EV/EBITDA 19.9 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate.
Analysis Summary
Elanco Animal Health Incorporated reported revenue of $4.71B in the most recent fiscal year, growing at a 5-year CAGR of 7.6%.
Trailing-twelve-month margins: gross margin 52.6%, operating margin 9.2%, net margin -4.0%.
At $24.10 (closing price, November 2, 2026), ELAN has negative trailing earnings (P/E not meaningful) and an ROE of -3.02%. Market capitalisation stands at $12.0B, placing it among large-cap names.
Balance sheet quality for ELAN: debt-to-equity ratio of 0.59, current ratio of 2.05 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.83 |
| EV / EBITDA | 19.9 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ELAN | Elanco Animal Health Incorporated | $12.0B | 1.83 | -3.0% | |
| MRK | Merck & Co., Inc. | $366.0B | 152.95 | 8.77 | 5.1% |
| IDXX | IDEXX Laboratories, Inc. | $52.9B | 45.60 | 28.32 | 71.2% |
| NEOG | Neogen Corporation | $2.6B | 1.24 | -2.7% | |
| ZTS | Zoetis Inc. | $34.4B | 13.70 | 11.03 | 69.3% |
Price
| Price | $24.10 (closing price, November 2, 2026) |
| Market Cap | $12.0B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | -3.02% |
| Return on Invested Capital | 3.92% |
| Return on Assets | -1.47% |
| Gross Margin | 52.59% |
| Operating Margin | 9.20% |
| Net Margin | -3.96% |
Related companies: MRK · IDXX · NEOG · ZTS
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ELAN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks